GlassScriptPhysician profile
Jacob S Appelbaum
NPI 1558604322
$8,131.77
in general payments reported to CMS, 2019-2025
11 companies · $3,401 in 2025
The $3,401 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $289 · 2023: $238 · 2024: $4,204 · 2025: $3,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,064 · Food and Beverage: $711 · Education: $68.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,063.75 |
| Food and Beverage | $710.86 |
| Education | $68.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,110.00 | 2024 | |
| Syndax Pharmaceuticals, INC. | $3,170.03 | 2025 | Revuforj |
| Celgene Corporation | $212.11 | 2022-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2023 | Calquence |
| Rigel Pharmaceuticals, INC. | $112.54 | 2023-2024 | Tavalisse, Rezlidhia |
| Stemline Therapeutics INC. | $108.27 | 2025 | Elzonris |
| Astellas Pharma Global Development | $107.02 | 2022-2024 | Xospata |
| Genentech, INC. | $85.87 | 2022-2023 | Lunsumio |
| Daiichi Sankyo INC. | $73.73 | 2022 | |
| Genentech USA, INC. | $17.20 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Appelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.